UroGen Pharma - About the company
UroGen Pharma is a public company based in Ra anana (Israel), founded in 2004. It operates as a Developer of therapeutics to treat urothelial and specialty cancers. UroGen Pharma has raised $7M in funding from Sonostar Ventures. The company has 14 active competitors, including 2 funded and 5 that have exited. Its top competitors include companies like Lipella, Protara Therapeutics and Prokarium.
Company Details
Developer of therapeutics to treat urothelial and specialty cancers. The company uses proprietary technology RTGel to deliver targeted therapies which include "Jelmyto" for the treatment of adult patients with low-grade Upper Tract Urothelial Cancer.
- Website
- www.urogen.com/
- Social
- Email ID
- *****@urogen.com
Key Metrics
Founded Year
2004
Location
Ra anana, Israel
Stage
Public
Total Funding
$7M in 4 rounds
Latest Funding Round
Investors
Ranked
1st among 14 active competitors
Employee Count
343 as on Sep 30, 2026
Investment & Acquisitions
Exit Details
Public
Legal entities associated with UroGen Pharma
UroGen Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
UroGen Pharma Ltd CIN: 4365405 , Israel, Active | Apr 27, 2004 | - | - | - |
UroGen Pharma's IPO details
UroGen Pharma got listed on May 04, 2017.
Click here to take a look at UroGen Pharma's IPO in detail
Sign up to download UroGen Pharma's company profile
UroGen Pharma's funding and investors
UroGen Pharma has raised a total funding of $7M over 4 rounds. Its first funding round was on May 22, 2013. Its latest funding round was a Post IPO round on Jul 27, 2023 for $*****. 5 investors participated in its latest round. UroGen Pharma has 14 institutional investors.
Here is the list of recent funding rounds of UroGen Pharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jul 27, 2023 | 3888267 | Post IPO | 2703059 | 1567988 | 3065101 | 7586009 |
Mar 18, 2021 | 8222060 | Post IPO | 9655654 | 1019961 | 1881162 | |
2016 | 5147 | Series B | 3688 | 2485 | 5527 |
Access funding benchmarks and valuations. Sign up today!View details of UroGen Pharma's funding rounds and investors
UroGen Pharma's founders and board of directors
Founder? Claim ProfileUroGen Pharma's employee count trend
UroGen Pharma has 343 employees as of Sep 26. Here is UroGen Pharma's employee count trend over the years:
Uncover UroGen Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
UroGen Pharma's Competitors and alternates
Top competitors of UroGen Pharma include Lipella, Protara Therapeutics and Prokarium. Here is the list of Top 10 competitors of UroGen Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st | UroGen Pharma 2004, Ra anana (Israel), Public | Developer of therapeutics to treat urothelial and specialty cancers | $7M | 66/100 | |
2nd | Lipella 2005, Pittsburgh (United States), Public | Developer of lipid-based therapies for common bladder syndromes | $3.37M | 57/100 | |
3rd |  Protara Therapeutics 2017, New York City (United States), Public | Developer of cell therapies to treat lymphatic malfunctions | - | 52/100 | |
4th |  Prokarium 2012, London (United Kingdom), Series C | Developer of bacterial immunotherapy treatments for various types of cancer | $70M | 52/100 | |
5th | Relmada 2007, Blue Bell (United States), Public | Developing innovative therapies for debilitating disorders, improving human health | $13M | 51/100 | |
6th |  Asieris Pharmaceuticals 2010, Radnor (United States), Unfunded | Developer of drugs for the treatment of genitourinary tumors and other major diseases | - | - | 50/100 |
7th |  Rainer Theraputics 2010, San Leandro (United States), Deadpooled | Developer of antibody based therapeutics for bladder cancer | $156M | 35/100 | |
8th | Tengion 2004, Audubon (United States), Deadpooled | Regenerative medicine company developing neo-organs & neo-tissues. | $143M | 35/100 | |
9th | Developer of drugs for treating cancer | $6.97M | 34/100 | ||
10th |  OncoSTING 2018, Baltimore (United States), Funding Raised | Developer of immunotherapy for bladder cancer | - | 32/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on UroGen Pharma's competitors? Click here to see the top ones
UroGen Pharma's Investments and acquisitions
UroGen Pharma has a total of 1 investment in INTRAGEL. UroGen Pharma has not made any acquisitions as of now.Reports related to UroGen Pharma
Here is the latest report on UroGen Pharma's sector:
News related to UroGen Pharma
Filter this listMedia has covered UroGen Pharma for a total of 22 events in the last 1 year, 14 of them have been about company updates and 1 about partnerships.
•
UroGen Pharma GAAP EPS of -$0.03 misses by $0.13, revenue of $89M misses by $0.91M (URGN:NASDAQ)Seeking Alpha•Nov 04, 2026•UroGen Pharma
•
UroGen expects profitability and positive cash flow in Q4 2026 as ZUSDURI grows 35% sequentially (NASDAQ:URGN)Seeking Alpha•Nov 04, 2026•UroGen Pharma
•
•
Coastal Bridge Advisors LLC Acquires Shares of 37,000 Urogen Pharma $URGNAug 28, 2026•UroGen Pharma, Coastal Bridge Advisors, Jefferies
•
Palo Alto Investors LP Makes New $901.60 Million Investment in Urogen Pharma $URGNWatch List News•Aug 28, 2026•UroGen Pharma, Palo Alto Investors
•
UroGen Pharma Announces Strategic Collaboration and Investment Agreement with IntraGelGlobeNewswire•Aug 20, 2026•UroGen Pharma, INTRAGEL
•
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBCStock Screener•Aug 17, 2026•UroGen Pharma
•
Urogen Pharma $URGN Shares Acquired by California State Teachers Retirement SystemAug 15, 2026•CalSTRS, UroGen Pharma, Hennionandwalsh
•
UroGen Pharma Announces Second Quarter 2026 Financial ResultsGlobeNewswire•Aug 05, 2026•UroGen Pharma
•
UroGen Pharma Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103GlobeNewswire•Jul 15, 2026•UroGen Pharma
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about UroGen Pharma
Explore our recently published companies
- Am Jain College - Chennai based, Unfunded company
- CommerceShop - Atlanta based, 2009 founded, Unfunded company
- Ukrainian State University of Railway - Ukraine based, Unfunded company
- Limitless Business - 1999 founded, Unfunded company
- Carrelle - Los Angeles based, 2018 founded, Unfunded company
- TIPSY FASHIONS - India based, 2011 founded, Unfunded company
